Wednesday, 14 October 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· May 20, 2026

Target Corporation Reports First Quarter Earnings

View original at finance.yahoo.com
“First quarter operating income and Adjusted operating income³ were $1.1 billion”
Verbatim excerpt from the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Full-year 2026 operating income margin rate expected to be more than 20 basis points higher than the 4.6% Adjusted operating income margin in 2025.

    60% confidence
  • Target expects net sales growth of around 4% for full-year 2026, two percentage points higher than the prior guidance range, with growth in every quarter of the year.

    60% confidence
  • Non-merchandise sales grew nearly 25%, reflecting strong growth in Roundel ad revenue, Target Circle 360 membership revenue, and the Target+ marketplace.

    60% confidence
  • Q1 2026 GAAP EPS of $1.71 was 24% lower than prior-year GAAP EPS of $2.27, which included non-recurring legal settlement gains.

    60% confidence
  • Target expects 2026 GAAP and Adjusted EPS near the high end of the prior guidance range of $7.50 to $8.50.

    60% confidence
  • Digital comparable sales grew 8.9%, led by more than 27% growth in same-day delivery powered by Target Circle 360.

    60% confidence
  • Net sales in all six core merchandising categories were higher than a year ago in Q1 2026.

    60% confidence
  • Q1 2026 results were stronger than expected, with the company's clarified strategy showing early signs of resonating with guests and driving broad-based growth.

    60% confidence
  • Target acknowledges significant remaining work and is focused on long-term consistent growth, disciplined flexibility in an uncertain environment, and bold investment in team, capabilities, and guest experience.

    60% confidence

Data points we hold from this source

Target Corporation · comparable traffic growth4.4 percent
Target Corporation · merchandise sales growth6.4 percent
Target Corporation · operating income change vs prior adjusted29.1 percent
Target Corporation · operating income1.1 USD
Target Corporation · comparable store sales growth4.7 percent
Target Corporation · eps guidance high8.50 USD
Target Corporation · eps guidance low7.50 USD
Target Corporation · non merchandise sales growth24.6 percent
Target Corporation · operating income change vs prior gaap-22.9 percent
Target Corporation · digital comparable sales growth8.9 percent
Target Corporation · eps adjusted1.30 USD
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com
Target Corporation Reports First Quarter Earnings — Source | Via News | ViaNews EU